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 ABSTRACT 
Type 2 diabetes (T2D) is characterized by insulin resistance and β-cell failure, abdominal 
obesity, hypertension and dyslipidemia. These symptoms are also characteristic of states of 
hypercortisolism. The purpose of this thesis was to investigate how cortisol and regulation of 
the hypothalamus-pituitary-adrenal (HPA) axis is affected in subjects with T2D compared with 
healthy subjects (study I). We investigated the effects of improved insulin sensitivity and β-cell 
function during treatment with pioglitazone (study II and III) or sitagliptin (study IV), as well 
as effect of gender (study I and III), on serum cortisol and the HPA axis. We further examined 
the relationship between cortisol and insulin-like growth factor-I (IGF-I) and hepatic insulin 
sensitivity assessed using IGF-binding protein-1 (IGFBP-1). 
 
Is adrenal sensitivity to ACTH affected by T2D or gender? (Study I) 
Serum cortisol was measured basally, after stimulation of the HPA axis with 1 μg 
adrenocorticotropic hormone (ACTH) and feedback inhibition with 0.25 mg dexamethasone 
(DEX) in patients with T2D (n = 21, HbA1c = 49 ± 2 mmol/mol) and healthy controls (n = 39). 
Adrenal sensitivity to ACTH was higher in healthy women compared to men. This gender 
difference was lost in T2D, due to increased cortisol response in men. Neither basal serum 
cortisol nor sensitivity to DEX differed between subjects with T2D and controls.  
 
Effect of pioglitazone on cortisol and IGF-I in T2D and IGT (Study II) 
Overweight men (BMI ≥28 kg/m2) with T2D (n = 10, HbA1c = 70 ± 7) and impaired glucose 
tolerance (IGT; n = 10) were treated with pioglitazone 30-45 mg daily for 12 weeks in addition 
to pre-existing therapy. Basal and stimulated cortisol did not differ at baseline. Improved insulin 
sensitivity and β-cell function after treatment was associated with decreased basal and peak 
cortisol after ACTH in T2D, while IGF-I increased. Paradoxically, basal and peak cortisol 
increased in IGT.  
 
Are there gender differences in the effects of pioglitazone in T2D? (Study III) 
Men (n = 28) and women (n = 20) with T2D and HbA1c >57 mmol/mol despite treatment with 
metformin and sulphonylurea were treated with pioglitazone 30-45 mg daily for 26 weeks. 
Basal cortisol increased in women despite improved insulin sensitivity. IGF-I and IGFBP-1 
increased regardless of gender. 
 
Is sitagliptin effect related to cortisol or hepatic insulin sensitivity? (Study IV) 
Patients admitted to hospital for ACS and in whom an oral glucose tolerance test revealed 
previously unknown T2D (n = 24) or IGT (n = 47) were randomized to sitagliptin 100 mg once 
daily for 12 weeks, or placebo. Cortisol decreased regardless of treatment, but was unaffected 
by sitagliptin as was IGF-I and IGFBP-1. 
 
Conclusions 
Study I showed that adrenal sensitivity to ACTH is elevated in men with T2D, abolishing the 
gender difference seen in healthy subjects. This underscores the importance of accounting for 
gender in future studies on the HPA axis and T2D. In study II and III, improved insulin 
sensitivity and β-cell function by pioglitazone was associated with changes in basal and 
stimulated cortisol, but the effect differed between groups. IGF-I increased during pioglitazone 
therapy in patients with T2D. This may be an effect of improved lipid metabolism and 
contribute to improved insulin sensitivity. Cortisol levels decreased over the coming weeks 
after ACS, along with improved insulin sensitivity (study IV). The effect of sitagliptin did not 
appear to be exerted via lowering cortisol, or increasing hepatic insulin sensitivity as measured 
by IGFBP-1. Differences in findings between our studies may depend on heterogeneity of the 
groups, as e.g. metabolic control and obesity affect the HPA axis. 
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